Abstract
Malignant tumour osteolysis is a frequent complication of cancers and multiple myeloma. It can cause skeletal related-events including pathological fractures, spinal cord compression, bone pain or hypercalcemia, with a significant alteration of quality of life and survival. Bisphosphonates (BP) play an important role in the management of this malignant osteolysis, via an inhibition of osteoclastmediated bone resorption, and a potential direct anti-tumour activity. Novel therapeutic targets such as specific RANKL antibodies are being investigated currently and are promising.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
